Clinical trial
A Phase 3 Randomized, Double-blinded, Active-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
NCT06081062 is registered in ClinicalTrials.gov with ISU Abxis Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-blinded, Active-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
- Lead sponsor
- ISU Abxis Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- April 14, 2023
- Completion date
- December 31, 2025
- Enrollment
- 24 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.